Suicidal ideation among people with Parkinson's disease and comparison with a control group.
Parkinson's disease
cohort
depression
ideation
suicide
Journal
International journal of geriatric psychiatry
ISSN: 1099-1166
Titre abrégé: Int J Geriatr Psychiatry
Pays: England
ID NLM: 8710629
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
15
01
2023
accepted:
18
04
2023
medline:
8
5
2023
pubmed:
6
5
2023
entrez:
6
5
2023
Statut:
ppublish
Résumé
Detection of suicidal ideation (SI) is key for trying to prevent suicide. The aim of this study was to analyze the frequency of SI and related factors in Spanish people with Parkinson's Disease (PwPD) and to compare them with a control group. PD patients and controls recruited from the Spanish cohort COPPADIS from January 2016 to November 2017 were included. Two visits were conducted: V0 (baseline); V2 (2-year ± 1 month follow-up). SI was defined as a score ≥1 on item nine of the Beck Depression Inventory-II (BDI-II). Regression analyses were conducted to identify factors related to SI. At baseline, 693 PwPD (60.2% males; 62.59 ± 8.91 years old) and 207 controls (49.8% males; 60.99 ± 8.32 years old) were included. No differences between PwPD and controls were detected in SI frequency at either V0 (5.1% [35/693] vs. 4.3% [9/207]; p = 0.421) or at V2 (5.1% [26/508] vs. 4.8% [6/125]; p = 0.549). Major depression (MD) and a worse quality of life were associated with SI at both visits in PwPD: V0 (MD, OR = 5.63; p = 0.003; PDQ-39, OR = 1.06; p = 0.021); V2 (MD, OR = 4.75; p = 0.027; EUROHIS-QOL8, OR = 0.22; p = 0.006). A greater increase in the BDI-II total score from V0 to V2 was the only factor predicting SI at V2 (OR = 1.21; p = 0.002) along with an increase in the total number of non-antiparkinsonian drugs (OR = 1.39; p = 0.041). The frequency of SI (5%) in PwPD was similar to in controls. Depression, a worse quality of life, and a greater comorbidity were related to SI.
Sections du résumé
BACKGROUND
Detection of suicidal ideation (SI) is key for trying to prevent suicide. The aim of this study was to analyze the frequency of SI and related factors in Spanish people with Parkinson's Disease (PwPD) and to compare them with a control group.
METHODS
PD patients and controls recruited from the Spanish cohort COPPADIS from January 2016 to November 2017 were included. Two visits were conducted: V0 (baseline); V2 (2-year ± 1 month follow-up). SI was defined as a score ≥1 on item nine of the Beck Depression Inventory-II (BDI-II). Regression analyses were conducted to identify factors related to SI.
RESULTS
At baseline, 693 PwPD (60.2% males; 62.59 ± 8.91 years old) and 207 controls (49.8% males; 60.99 ± 8.32 years old) were included. No differences between PwPD and controls were detected in SI frequency at either V0 (5.1% [35/693] vs. 4.3% [9/207]; p = 0.421) or at V2 (5.1% [26/508] vs. 4.8% [6/125]; p = 0.549). Major depression (MD) and a worse quality of life were associated with SI at both visits in PwPD: V0 (MD, OR = 5.63; p = 0.003; PDQ-39, OR = 1.06; p = 0.021); V2 (MD, OR = 4.75; p = 0.027; EUROHIS-QOL8, OR = 0.22; p = 0.006). A greater increase in the BDI-II total score from V0 to V2 was the only factor predicting SI at V2 (OR = 1.21; p = 0.002) along with an increase in the total number of non-antiparkinsonian drugs (OR = 1.39; p = 0.041).
CONCLUSION
The frequency of SI (5%) in PwPD was similar to in controls. Depression, a worse quality of life, and a greater comorbidity were related to SI.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e5919Investigateurs
Adarmes Astrid Daniela
(A)
Marta Almeria
(M)
Maria Gema Alonso Losada
(MG)
Araceli Alonso Cánovas
(A)
Fernando Alonso Frech
(F)
Ruben Alonso Redondo
(R)
Ignacio Álvarez
(I)
María Álvarez Sauco
(M)
Ángel Aneiros Díaz
(Á)
Sandra Arnáiz
(S)
Sonia Arribas
(S)
Arancha Ascunce Vidondo
(A)
Miquel Aguilar
(M)
Maria Asunción Ávila
(MA)
Noemí Bernardo Lambrich
(N)
Helena Bejr-Kasem
(H)
Marta Blázquez Estrada
(M)
Maria Ángeles Botí González
(MÁ)
Carmen Borrue
(C)
Maria Teresa Buongiorno
(MT)
Carolina Cabello González
(C)
Iria Cabo López
(I)
Nuria Caballol
(N)
Ana Cámara Lorenzo
(A)
Héctor Canfield Medina
(H)
Fátima Carrillo
(F)
Francisco José Carrillo Padilla
(FJ)
Elena Casas
(E)
Maria José Catalán
(MJ)
Pedro Clavero
(P)
A Cortina Fernández
(A)
Marina Cosgaya
(M)
Anna Cots Foraster
(A)
Ane Crespo Cuevas
(A)
Esther Cubo
(E)
Teresa de Deus Fonticoba
(T)
Oriol de Fábregues-Boixar
(O)
M Díez-Fairen
(M)
Julio Dotor García-Soto
(J)
Elena Erro
(E)
Sonia Escalante
(S)
Elena Estelrich Peyret
(E)
Noelia Fernández Guillán
(N)
Pedro Gámez
(P)
Mercedes Gallego
(M)
Juan García Caldentey
(J)
Cristina García Campos
(C)
Cristina García Díez
(C)
Jose Manuel García Moreno
(JM)
Itziar Gastón
(I)
María Del Pilar Gómez Garre
(MDP)
Víctor Gómez Mayordomo
(V)
Javier González Aloy
(J)
Isabel González-Aramburu
(I)
Jessica González Ardura
(J)
Beatriz González García
(B)
Maria Josefa González Palmás
(MJ)
Gabriel Ricardo González Toledo
(GR)
Ana Golpe Díaz
(A)
Mireia Grau Solá
(M)
Gemma Guardia
(G)
Jorge Hernández Vara
(J)
Andrea Horta-Barba
(A)
Daniel Idoate Calderón
(D)
Jon Infante
(J)
Silvia Jesús
(S)
Jaime Kulisevsky
(J)
Mónica Kurtis
(M)
Carmen Labandeira
(C)
Miguel Ángel Labrador Espinosa
(MÁ)
Francisco Lacruz
(F)
Melva Lage Castro
(M)
Sonia Lastres Gómez
(S)
Inés Legarda
(I)
Nuria López Ariztegui
(N)
Luis Manuel López Díaz
(LM)
Daniel López Domínguez
(D)
Lydia López Manzanares
(L)
Balbino López Seoane
(B)
Sara Lucas Del Pozo
(S)
Yolanda Macías
(Y)
Marina Mata
(M)
Gloria Martí Andres
(G)
Maria José Martí
(MJ)
Juan Carlos Martínez Castrillo
(JC)
Pablo Martinez-Martin
(P)
Darrian McAfee
(D)
Maria Teresa Meitín
(MT)
Zebenzui Mendoza Plasencia
(Z)
Manuel Menéndez González
(M)
Carlota Méndez Del Barrio
(C)
Pablo Mir
(P)
Javier Miranda Santiago
(J)
Maria Isabel Morales Casado
(MI)
Antonio Moreno Diéguez
(A)
Víctor Nogueira
(V)
Alba Novo Amado
(A)
Sabela Novo Ponte
(S)
Carlos Ordás
(C)
Javier Pagonabarraga
(J)
Isabel Pareés
(I)
Berta Pascual-Sedano
(B)
Pau Pastor
(P)
Aída Pérez Fuertes
(A)
Rafael Pérez Noguera
(R)
Ana Planas-Ballvé
(A)
Lluís Planellas
(L)
Marian Ángeles Prats
(MÁ)
Cristina Prieto Jurczynska
(C)
Víctor Puente
(V)
Mercedes Pueyo Morlans
(M)
Arnau Puig Daví
(A)
Nuria Redondo Rafales
(N)
Luisa Rodríguez Méndez
(L)
Amparo Belén Rodríguez Pérez
(AB)
Florinda Roldán
(F)
María Ruíz De Arcos
(M)
Javier Ruíz Martínez
(J)
Pilar Sánchez Alonso
(P)
Macarena Sánchez-Carpintero
(M)
Gema Sánchez Díez
(G)
Antonio Sánchez Rodríguez
(A)
Pilar Santacruz
(P)
Diego Santos García
(D)
José Clemente Segundo Rodríguez
(JC)
Manuel Seijo
(M)
María Sierra Peña
(M)
Berta Solano Vila
(B)
Ester Suárez Castro
(E)
Juan Pablo Tartari
(JP)
Caridad Valero
(C)
Laura Vargas
(L)
Lydia Vela
(L)
Clara Villanueva
(C)
Bárbara Vives
(B)
Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatr. 1992;149:443-454.
Slaughter JR, Slaughter KA, Nichols D, Holmes SE, Martens MP. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease. J Neuropsychiatr Clin Neurosci. 2001;13(2):187-196. https://doi.org/10.1176/jnp.13.2.187
Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leenjens AF. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord. 2008;23(2):183-189. https://doi.org/10.1002/mds.21803
Chendo I, Silva C, Duarte GS, et al. Frequency of depressive disorders in Parkinson's disease: a systematic review and meta-analysis. J Park Dis. 2022;12(5):1409-1418. (epub ahead of print). https://doi.org/10.3233/jpd-223207
Ehrt U, Brønnick K, Leentjens AFG, Larsen JP, Aarsland D. Depressive symptom profile in Parkinson’s disease: a comparison with depression in elderly patients without Parkinson’s disease. Int J Geriatr Psychiatr. 2006;21(3):252-258. https://doi.org/10.1002/gps.1456
Santos-García D, De Deus FT, Cores BC, et al. Mood in Parkinson's disease: from early-to late-stage disease. Int J Geriatr Psychiatr. 2021;36(5):627-646. https://doi.org/10.1002/gps.5461
Santos García D, de Deus Fonticoba T, Suárez Castro E, et al. Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson's disease patients: results from the COPPADIS Study Cohort. Parkinsonism Relat Disord. 2019;66:151-157. https://doi.org/10.1016/j.parkreldis.2019.07.031
Myslobodsky M, Lalonde FM, Hicks L. Are patients with Parkinson’s disease suicidal? J Geriatr Psychiatr Neurol. 2001;14(3):120-124. https://doi.org/10.1177/089198870101400304
Nazem S, Siderowf AD, Duda JE, et al. Suicidal and death ideation in Parkinson's disease. Mov Disord. 2008;23(11):1573-1579. https://doi.org/10.1002/mds.22130
Chen YY, Yu S, Hu YH, et al. Risk of suicide among patients with Parkinson disease. JAMA Psychiatr. 2021;78(3):293-301. https://doi.org/10.1001/jamapsychiatry.2020.4001
Berardelli I, Belvisi D, Nardella A, et al. Suicide in Parkinson's disease: a systematic review. CNS Neurol Disord Drug Targets. 2019;18(6):466-477. https://doi.org/10.2174/1871527318666190703093345
Linse K, Fauser M, Ossig C, Hermann A, Storch A. Feasibility and effectiveness of a low-threshold psychoeducative group-intervention for depression in Parkinson’s disease. Mov Disord. 2016;31(Suppl 2):S491.
Hoertel N, Blanco C, Olfson M, et al. A comprehensive model of predictors of suicide attempt in depressed individuals and effect of treatment-seeking behavior. J Clin Psychiatry. 2018;79(5). https://doi.org/10.4088/jcp.17m11704
Shepard MD, Perepezko K, Broen MPG, et al. Suicide in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2019;90(7):822-829. https://doi.org/10.1136/jnnp-2018-319815
Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010;67(1):58-63. https://doi.org/10.1001/archneurol.2009.294
Du J, Liu X, Zhou X, et al. Parkinson's disease-related risk of suicide and effect of deep brain stimulation: meta-analysis. Parkinsons Dis. 2020;2020:8091963. https://doi.org/10.1155/2020/8091963
van Heeringen K, Mann JJ. The neurobiology of suicide. Lancet Psychiatr. 2014;1:63-72. https://doi.org/10.1016/s2215-0366(14)70220-2
Oquendo MA, Sullivan GM, Sudol K, et al. Toward a Biosignature for suicide. Am J Psychiatr. 2014;171(12):1259-1277. https://doi.org/10.1176/appi.ajp.2014.14020194
Stone DM, Crosby AE. Suicide prevention. Am J Lifestyle Med. 2014;8(6):404-420. https://doi.org/10.1177/1559827614551130
Santos García D, Jesús S, Aguilar M, et al. COPPADIS-2015 (COhort of Patients with Parkinson's DIsease in Spain, 2015): an ongoing global Parkinson's disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation. Eur J Neurol. 2019;26(11):1399-1407. https://doi.org/10.1111/ene.14008
Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181-184. https://doi.org/10.1136/jnnp.55.3.181
Beck AT, Steer RA, Brown GK. Beck Depression Inventory-Second Edition, Manual, 1996. The Psychological Corporation.
Santos-García D, Mir P, Cubo E, et al. COPPADIS-2015 (COhort of Patients with Parkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression. BMC Neurol. 2016;16(1):26. https://doi.org/10.1186/s12883-016-0548-9
American Psychiatric Association. Diagnostic and Statical Manual of Mental Disorders. 4th ed. American Psychiatric Association; 1994.
Judd LL, Rapaport MH, Paulus MP, Brown JL. Subsyndromal symptomatic depression: a new mood disorder? J Clin Psychiatry. 1994;55(Suppl):18-28.
Ou R, Wei Q, Hou Y, et al. Suicidal ideation in early-onset Parkinson's disease. J Neurol. 2021;268(5):1876-1884. https://doi.org/10.1007/s00415-020-10333-4
Elfil M, Ahmed N, Alapati A, et al. Suicidal risk and demoralization in Parkinson disease. J Neurol. 2020;267(4):966-974. https://doi.org/10.1007/s00415-019-09632-2
Chendo I, Fabbri M, Godinho C, et al. High frequency of depressive disorders and suicidal phenomena in late-stage Parkinson´s disease - a cross-sectional study. J Geriatr Psychiatr Neurol. 2022:089198872211355. (ahead of print). https://doi.org/10.1177/08919887221135556
Belvisi D, Berardelli I, Ferrazzano G, et al. The clinical correlates of suicidal ideation in Parkinson's disease. Parkinsonism Relat Disord. 2019;63:54-59. https://doi.org/10.1016/j.parkreldis.2019.02.047
Berardelli I, Belvisi D, Corigliano V, et al. Suicidal ideation, perceived disability, hopelessness and affective temperaments in patients affected by Parkinson's disease. Int J Clin Pract. 2018;73(3):e13287. https://doi.org/10.1111/ijcp.13287
Kummer A, Cardoso F, Teixeira AL. Suicidal ideation in Parkinson's disease. CNS Spectr. 2009;14(8):431-436. https://doi.org/10.1017/s109285290002040x
Ozdilek B, Gultekin BK. Suicidal behavior among Turkish patients with Parkinson's disease. Neuropsychiatr Dis Treat. 2014;10:541-545. https://doi.org/10.2147/ndt.s60450
Kostić VS, Pekmezović T, Tomić A, et al. Suicide and suicidal ideation in Parkinson's disease. J Neurol Sci. 2010;289(1-2):40-43. https://doi.org/10.1016/j.jns.2009.08.016
Dissanayaka NN, Sellbach A, Matheson S, et al. Anxiety disorders in Parkinson's disease: prevalence and risk factors. Mov Disord. 2010;25(7):838-845. https://doi.org/10.1002/mds.22833
Pagano G, Taylor KI, Anzures-Cabrera J, et al. PASADENA investigators; prasinezumab study group. Trial of prasinezumab in early-stage Parkinson's disease. N Engl J Med. 2022;387(5):421-432. https://doi.org/10.1056/nejmoa2202867
Li W, Abbas MM, Acharyya S, et al. Suicide in Parkinson's disease. Mov Disord Clin Pract. 2018;5(2):177-182. https://doi.org/10.1002/mdc3.12599
Jeong SH, Hoon Kim S, Lee DW, Park EC, Jang SY. Association between new-onset Parkinson's disease and suicide risk in South Korea: a nationwide cohort study. BMC Psychiatr. 2022;22(1):341. https://doi.org/10.1186/s12888-022-03990-4
Rai N, Goyal V, Kumar N, et al. Neuropsychiatric co-morbidities in non-demented Parkinson′s disease. Ann Indian Acad Neurol. 2015;18:33-38.
Dumitru MM. Suicidal ideation in Parkinson’s disease. Park Relat Disord. 2016;22:e75. https://doi.org/10.1016/j.parkreldis.2015.10.115
Lee H, Myung W, Lee C, et al. Clinical epidemiology of long-term suicide risk in a nationwide population-based cohort study in South Korea. J Psychiatr Res. 2018;100:47-55. https://doi.org/10.1016/j.jpsychires.2018.01.018
Rezvani Z, Barr E, Gruber-Baldini A, et al. Parkinson’s disease, suicidal ideation and associated risk factors. Neurology. 2017;88(16 Suppl).
Santos García D, de Deus Fonticoba T, Cores C, et al. Predictors of clinically significant quality of life impairment in Parkinson's disease. NPJ Park Dis. 2021;7(1):118. https://doi.org/10.1038/s41531-021-00256-w
Pompili M, Forte A, Berman AL, Lamis DA. The association between physical illness/medical conditions and suicide risk. In: The International Handbook of Suicide Prevention. Wiley & Sons, Ltd; 2016:133-148.
Flament M, Loas G, Godefroy O, Krystkowiak P. Suicide without depression after withdrawal of a dopamine agonist in a patient with Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2011;23(4):E32. https://doi.org/10.1176/jnp.23.4.jnpe32
Solla P, Fasano A, Cannas A, Marrosu F. Suicide and dopamine agonist withdrawal syndrome in Parkinson's disease. Mov Disord. 2015;30(13):1859-1860. https://doi.org/10.1002/mds.26443
Fitzgerald ML, Kassir SA, Underwood MD, Bakalian MJ, Mann JJ, Arango V. Dysregulation of striatal dopamine receptor binding in suicide. Neuropsychopharmacology. 2017;42(4):974-982. https://doi.org/10.1038/npp.2016.124